GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (STU:NTY) » Definitions » EBITDA Margin %

Nabriva Therapeutics (STU:NTY) EBITDA Margin % : -466.41% (As of Jun. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nabriva Therapeutics's EBITDA for the three months ended in Jun. 2023 was €-11.08 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was €2.38 Mil. Therefore, Nabriva Therapeutics's EBITDA margin for the quarter that ended in Jun. 2023 was -466.41%.


Nabriva Therapeutics EBITDA Margin % Historical Data

The historical data trend for Nabriva Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics EBITDA Margin % Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,755.35 -1,016.02 -2,335.26 -174.24 -153.36

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.62 -123.07 -213.68 -111.79 -466.41

Competitive Comparison of Nabriva Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Nabriva Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nabriva Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's EBITDA Margin % falls into.



Nabriva Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nabriva Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-51.639/33.671
=-153.36 %

Nabriva Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-11.082/2.376
=-466.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nabriva Therapeutics  (STU:NTY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Nabriva Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nabriva Therapeutics (STU:NTY) Business Description

Traded in Other Exchanges
Address
Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (STU:NTY) Headlines

No Headlines